Alnylam Pharmaceuticals reported $42.36M in Interest Expense on Debt for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US $ 42.36M 5.55M
Amgen AMGN:US $ 295M 40M
Avrobio Inc AVRO:US 304K 101K
Biocryst Pharmaceuticals BCRX:US $ 23.84M 5.06M
Biomarin Pharmaceutical BMRN:US $ 3.81M 0.04M
Intercept Pharmaceuticals ICPT:US $ 6.67M 8.64M
Moderna Inc MRNA:US 6M 0
Novartis NVS:US $ 201M 5M
Ptc Therapeutics PTCT:US $ 23.61M 1.01M
Regeneron Pharmaceuticals REGN:US $ 13.6M 0.5M
Regulus Therapeutics RGLS:US $ 0.16M 0.06M
Sarepta Therapeutics SRPT:US $ 15.8M 0.25M
Vertex Pharmaceuticals VRTX:US $ 14.9M 0.19M
YTE INCY:US $ 0.68M 0.07M